Literature DB >> 15270757

Dialyzability of the antiepileptic drug zonisamide in patients undergoing hemodialysis.

Yoshio Ijiri1, Toru Inoue, Fumio Fukuda, Kaoru Suzuki, Toyohide Kobayashi, Nobuhisa Shibahara, Hiroshi Takenaka, Kazuhiko Tanaka.   

Abstract

PURPOSE: The influence of hemodialysis on plasma zonisamide (ZNS) concentration has not been clarified. In this study, the dialyzability of ZNS during hemodialysis was investigated in four ZNS-treated women with systemic lupus erythematosus complicated by seizures.
METHODS: The total and unbound plasma concentrations of ZNS were measured before and after hemodialysis. The concentration of ZNS in the spent dialysate also was determined.
RESULTS: The reduction in plasma ZNS concentration after a 4.5-h hemodialysis was 52.0 +/- 7.6%, and the dialyzer (BLF-16GW) clearance of ZNS was 55.1 +/- 7.0 ml/min. Dosage was gradually increased up to 200 to 500 mg/day, and the seizures were controlled satisfactorily.
CONCLUSIONS: The plasma concentration of ZNS was reduced by approximately 50% during one session of dialysis. For patients undergoing daytime hemodialysis sessions every 2 or 3 days, the usual dosage of ZNS (4-8 mg/kg/day) may be prescribed once a day in the evening. If seizures occur after hemodialysis, a supplemental daily dose may be prescribed in the morning.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15270757     DOI: 10.1111/j.0013-9580.2004.30603.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  3 in total

1.  Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications.

Authors:  Matthew D Krasowski
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-11

Review 2.  An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs.

Authors:  Shery Jacob; Anroop B Nair
Journal:  Drugs R D       Date:  2016-12

3.  Comparing Zonisamide With Sodium Valproate in the Management of Migraine Headaches: Double-Blind Randomized Clinical Trial of Efficacy and Safety.

Authors:  Farhad Assarzadegan; Hanif Tabesh; Seyed-Mostafa Hosseini-Zijoud; Andrew David Beale; Arya Shoghli; Mahmood Ghafoori Yazdi; Behnam Mansouri; Omid Hesami; Nahid Beladi Moghadam; Hosein Delavar Kasmaei
Journal:  Iran Red Crescent Med J       Date:  2016-04-30       Impact factor: 0.611

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.